MEDICAL ONCOLOGY

CLOSED TO RECRUITMENT — AUSTRALIA

Abbrev. Title

C3441021 TALAPRO-2

Protocol Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib in Combination with Physician's Choice of Enzalutamide or Abiraterone Acetate/Prednisone in Metastatic Castration-Resistant Prostate Cancer with DNA Damage Repair Deficiencies

C-550-01

A Phase 1/2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination with AGEN2034 in Subjects with Metastatic or Locally Advanced Solid Tumours, and Expansion Into Select Solid Tumours

CA209-7DX Checkmate7DX

A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer

CA209-901 Checkmate-901

A Phase 3, Open-Label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer

CA209-914 Checkmate-914

A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination Vs Placebo in Participants with Localized Renal Cell Carcinoma who Underwent Radical or Partial Nephrectomy and who are at High Risk of Relapse

CA209-9KD Checkmate9KD

A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-Resistant Metastatic Prostate Cancer

CanStem111P

A Phase III Study of BBI-608 plus Nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma

CANVACCS

CANcer patients' perspectives on coronavirus VACCination Survey (CANVACCS) research project

CBT-501

APOLLO-1

CLEE011A2301

MONALEESA-2

A Phase 1/2 Open Label, Multi-Center Dose Escalation and Expansion Study of Combination Immunotherapy APL-501 (Anti-PD-1) or Nivolumab with APL-101 (C-MET Inhibitor) in Locally Advanced or Metastatic Hepatocellular Carcinoma and Renal Cell Carcinoma

A Randomized Double-Blind, Placebo-Controlled Study of LEE011 in Combination with Letrozole for the Treatment of Postmenopausal Women with Hormone Receptor Positive, HER2-Negative, Advanced Breast Cancer who Received No Prior Therapy for Advanced Disease